

MERRIMACK PHARMACEUTICALS INC
 Form 3
 April 10, 2017

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>Â Drummond Daryl C</p> <p>(Last) (First) (Middle)</p> <p>C/O MERRIMACK PHARMACEUTICALS, INC., Â ONE KENDALL SQUARE, SUITE B7201</p> <p>(Street)</p> <p>CAMBRIDGE, Â MA Â 02139</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>03/31/2017</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>MERRIMACK PHARMACEUTICALS INC [MACK]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p>___ Director ___ 10% Owner ___X___ Officer ___ Other (give title below) (specify below)</p> <p>Head of Research</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p>___X___ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person</p>
--	---	--	--	---	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	92,420	D	Â
Common Stock	9,311	I	By Wife

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	Â <u>(1)</u>	02/01/2020	Common Stock	80,000	\$ 2.12	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	10/15/2020	Common Stock	27,500	\$ 2.69	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	05/03/2021	Common Stock	20,000	\$ 5.54	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	08/22/2022	Common Stock	14,100	\$ 7.53	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	03/11/2023	Common Stock	50,000	\$ 6.35	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	02/10/2024	Common Stock	30,000	\$ 5.02	D	Â
Stock Option (right to buy)	Â <u>(2)</u>	02/08/2025	Common Stock	32,500	\$ 9.08	D	Â
Stock Option (right to buy)	Â <u>(3)</u>	02/07/2026	Common Stock	42,000	\$ 5.42	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	07/03/2017	Common Stock	4,097	\$ 2.69	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	07/03/2017	Common Stock	900	\$ 5.54	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	06/02/2017	Common Stock	1,400	\$ 7.53	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	06/02/2017	Common Stock	1,700	\$ 6.35	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	06/02/2017	Common Stock	1,796	\$ 5.02	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	06/02/2017	Common Stock	599	\$ 9.08	I	By Wife
Stock Option (right to buy)	Â <u>(1)</u>	06/02/2017	Common Stock	333	\$ 5.42	I	By Wife

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Reporting Owners

Drummond Daryl C
C/O MERRIMACK PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, SUITE B7201
CAMBRIDGE, MA 02139

Â Â Â Head of
Research Â

Signatures

/s/ Brian J. Kickham,
attorney-in-fact

04/10/2017

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option is fully vested.
- (2) This option vested as to 1/12th of the total number of shares on 5/9/15 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/9/18.
- (3) This option vested as to 1/12th of the total number of shares on 5/8/16 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/8/19.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.